Disc Medicine (IRON) reported second-quarter 2026 financial results and provided updates across its hematology pipeline, including bitopertin, selcodebart and DISC-3405.
The company posted a net loss of $59.5 million for the quarter ended June 30, 2026, compared with $55.2 million a year earlier. Cash, cash equivalents and marketable securities were $717.7 million at quarter-end, with expected runway into 2029.
- Completed a Type A meeting with the FDA on bitopertin in EPP and aligned that the Phase 3 APOLLO study, if successful, can support a CRL response.
- APOLLO topline data are expected in Q4 2026, with a CRL response and FDA decision expected by mid-2027.
- Launched an Expanded Access Program for bitopertin for eligible EPP and XLP patients.
- RESTORE-PV Phase 2 enrollment for DISC-3405 in polycythemia vera was completed, with initial data expected in Q3 2026.
- R&D expenses were $46.9 million, while SG&A expenses were $18.1 million for the quarter.
$IRON Insider Trading Activity
$IRON insiders have traded $IRON stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $IRON stock by insiders over the last 6 months:
- JOHN D QUISEL (Chief Executive Officer) has made 0 purchases and 7 sales selling 80,264 shares for an estimated $5,694,850.
- JONATHAN YEN-WEN YU (Chief Operating Officer) has made 0 purchases and 6 sales selling 31,943 shares for an estimated $2,225,696.
- JEAN M. FRANCHI (Chief Financial Officer) has made 0 purchases and 6 sales selling 18,166 shares for an estimated $1,204,938.
- WILLIAM JACOB SAVAGE (Chief Medical Officer) has made 0 purchases and 5 sales selling 16,365 shares for an estimated $1,071,190.
- RAHUL KHARA (Chief Legal Officer) has made 0 purchases and 6 sales selling 12,853 shares for an estimated $893,500.
- PAMELA STEPHENSON (Chief Commercial Officer) sold 5,531 shares for an estimated $347,678
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IRON Hedge Fund Activity
We have seen 116 institutional investors add shares of $IRON stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC added 1,341,862 shares (+inf%) to their portfolio in Q1 2026, for an estimated $85,798,656
- BVF INC/IL added 622,312 shares (+95.7%) to their portfolio in Q1 2026, for an estimated $39,790,629
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 523,167 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $33,451,297
- STATE STREET CORP added 510,253 shares (+43.0%) to their portfolio in Q1 2026, for an estimated $32,625,576
- RA CAPITAL MANAGEMENT, L.P. added 474,089 shares (+24.0%) to their portfolio in Q1 2026, for an estimated $30,313,250
- BELLEVUE GROUP AG added 459,314 shares (+inf%) to their portfolio in Q1 2026, for an estimated $29,368,537
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 450,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $28,773,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
